AstraZeneca set to start COVID-19 antibody trials

AstraZeneca will start clinical trials of two antibodies targeting SARS-CoV-2, the virus that causes COVID-19, within the next two months. The two candidates have emerged from a partnership with Vanderbilt University in the US – focusing on up to six coronavirus-targeting neutralising antibodies – which was signed in April. The antibodies have the potential to

Continue Reading

Eli Lily commences trial for COVID-19 antibody treatment

Eli Lilly has recently begun dosing patients in the world’s first trial for treatment designed to attack SARS-CoV-2, the virus that causes COVID-19. This investigational treatment, referred to as LY-CoV555, is the first produced as a result of the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Scientists developed

Continue Reading

Karyopharm announce Xpovio meets endpoints in Phase III trial

The pharmaceutical company announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor). The drug in combination with once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd) met its primary endpoint of a statistically significant increase in progression-free survival (PFS) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd). The trial saw the

Continue Reading

New clinical trial to investigate affects of CBD on Parkinson’s related psychosis

A pioneering clinical trial is set to investigate the use of cannabidiol (CBD) in people with Parkinson’s-related psychosis. Parkinson’s UK will be partnering with scientists at King’s College London in the first large-scale trial which aims to provide preliminary evidence for the safety and efficacy of CBD to alleviate the symptoms of Parkinson’s-related psychosis, characterised by hallucinations and delusions.

Continue Reading